EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Virginia Anagnostopoulou iD, Christoforos K Travlos, Lucas Lage Marinho, Thomas A Mavrakanas, João Pedro Ferreira, Abhinav Sharma iD

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 10931-10949

DOI: 10.1111/dom.71230 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.08.2026. Verfasst von Virginia Anagnostopoulou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Metabolic Syndrome, Fibric Acids, Cardiovascular Diseases. Die Arbeit nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Mitacs Accelerate Program, Canadian Institutes of Health Research (CIHR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome. Although contemporary therapies such as sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and non‐steroidal mineralocorticoid receptor antagonists (nsMRA) have improved cardiovascular and renal outcomes, diabetes‐related microvascular complications remain common. Fibrates, traditionally used to lower triglycerides and increase high‐density lipoprotein cholesterol, activate peroxisome proliferator‐activated receptor‐α (PPAR‐α) and influence pathways involved in metabolic and vascular injury, including inflammation, oxidative stress, endothelial dysfunction, mitochondrial metabolism, lipid handling, fibrosis and angiogenesis. This review reappraises the potential role of fibrates within the CKLM syndrome framework, focusing on diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, peripheral artery disease and metabolic dysfunction‐associated steatotic liver disease. Clinical evidence is the strongest for diabetic retinopathy, where fenofibrate reduces retinopathy progression and the need for retinal laser therapy. Post hoc analyses also suggest favourable effects on albuminuria progression and chronic estimated glomerular filtration rate (eGFR) decline, although fibrates may cause a reversible rise in serum creatinine. Evidence for diabetic neuropathy remains limited, while clinical trials and real‐world studies suggest reductions in lower‐extremity amputations and diabetic foot complications. In liver disease, fenofibrate has shown modest benefit, whereas selective PPAR‐α modulators may more favourably influence liver enzymes, inflammation and non‐invasive fibrosis markers. Overall, fibrates may complement contemporary cardiometabolic therapies by targeting residual microvascular and liver‐related risk. However, dedicated outcome trials and improved patient stratification are needed before broader clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeFibric AcidsCardiovascular DiseasesHumansDiabetes Mellitus, Type 2Diabetic Nephropathies

Stichwörter der Autor:innen

cardiovascular‐kidney‐liver‐metabolic syndromefenofibratefibratesmetabolic dysfunction‐associated steatotic liver diseasemicrovascular complicationstype 2 diabetes mellitus

Substanzen

Fibric Acids

Autor:innen und Institutionen

  • Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
  • DREAM-CV Lab, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
  • Division of Cardiology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
  • Division of Clinical and Translational Research, Department of Medicine, McGill University, Montreal, Quebec, Canada.
  • McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
  • Division of Nephrology, Department of Medicine, McGill University Health Centre and Research Institute, Montreal, Québec, Canada.

ORCID-Profile: Virginia Anagnostopoulou, Abhinav Sharma

Förderung

  • Mitacs Accelerate Program
  • Canadian Institutes of Health Research (CIHR)

Zitieren

APA

Anagnostopoulou, V., Travlos, C. K., Marinho, L. L., Mavrakanas, T. A., Ferreira, J. P., & Sharma, A. (2026). Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates. Diabetes, Obesity and Metabolism, 28(12), 10931-10949. https://doi.org/10.1111/dom.71230

Vancouver

Anagnostopoulou V, Travlos CK, Marinho LL, Mavrakanas TA, Ferreira JP, Sharma A. Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates. Diabetes, Obesity and Metabolism. 2026;28(12):10931-10949. doi:10.1111/dom.71230

BibTeX
@article{Anagnostopoulou2026,
  author = {Anagnostopoulou, Virginia and Travlos, Christoforos K and Marinho, Lucas Lage and Mavrakanas, Thomas A and Ferreira, João Pedro and Sharma, Abhinav},
  title = {Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {10931--10949},
  doi = {10.1111/dom.71230}
}
Kostenlos starten →